Over 61 per cent of all deaths in India are due to lifestyle or non-communicable diseases (NCDs), most prevalent are - heart attack, diabetes, and high blood pressure. Not restricted to adults alone, lifestyle diseases have started hitting kids as well. The shift in purchasing power and the coming in of technology has changed the way our life functions now. Less physical activity, more availability of resources and no time to spare, we have become preys to some extremely uncommon diseases our grandparents had never even heard about back in the 60s and 70s.
India has the highest number of diabetics at 50.8 million according to the World Health Organization, though only 11% of the population has health insurance. This figure is set to increase to 73.5 million by 2025. Twenty-five million suffer from cardiovascular diseases which amount to 60% of the global figure. Overcrowding and bad living conditions also increase stress leading to coronary heart diseases, asthma and cancers. Urbanization makes for a sedentary life leading to greater obesity.
Companies making drugs for lifestyle diseases have bright long term future.
Launches of new products from its consumer healthcare portfolio (operates in four segments: pain-care, digestive health, allergy and vitamins, minerals supplements), along with brand extensions and access to innovative molecules from global parent under free licensing and continued domestic rural penetration strategies would create strong growth opportunities for the company
New product launches and price hikes of NLEM products (~25-28% of total sales) are expected to drive Sanofi’s topline growth.
Register for FREE to receive all our investment insights in your mailbox